ArticleRespiratory medicine case reports2017

Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.

Paul Zarogoulidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.